Loading…

Expression levels of the putative zinc transporter LIV‐1 are associated with a better outcome of breast cancer patients

We investigated the expression pattern of the breast cancer associated gene LIV‐1 on mRNA and protein level in 111 human breast cancer patients by in situ hybridization as well as immunohistochemistry and focused on the unknown potential of LIV‐1 expression levels as a prognostic marker. To our know...

Full description

Saved in:
Bibliographic Details
Published in:International journal of cancer 2005-12, Vol.117 (6), p.961-973
Main Authors: Kasper, Grit, Weiser, Armin A., Rump, Andreas, Sparbier, Katrin, Dahl, Edgar, Hartmann, Arndt, Wild, Peter, Schwidetzky, Uta, Castaños‐Vélez, Esmeralda, Lehmann, Kerstin
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We investigated the expression pattern of the breast cancer associated gene LIV‐1 on mRNA and protein level in 111 human breast cancer patients by in situ hybridization as well as immunohistochemistry and focused on the unknown potential of LIV‐1 expression levels as a prognostic marker. To our knowledge, this is the first study on endogenous LIV‐1 protein expression. Results of our study indicate that LIV‐1 mRNA and protein expression levels are only weakly correlated, suggesting posttranscriptional regulatory mechanisms. Furthermore, LIV‐1 mRNA quantity in combination with a positive ER status seem to represent a better marker than the progesterone receptor status according to the prognostic significance for relapse free survival (RFS). A negative correlation of LIV‐1 protein levels with tumor size, grade and stage reflects an association of LIV‐1 protein expression with less aggressive tumors. High LIV‐1 protein expression seems to be associated with a longer relapse free and overall survival in breast cancer patients with invasive ductal carcinoma. This association, however, seems to be dependent from other prognostic markers. Our data suggest that LIV‐1 is a promising candidate for a novel marker for breast cancer patients with better outcome. Furthermore, our study presents a revised cDNA sequence of LIV‐1 and demonstrates the localization of endogenous LIV‐1 in the endoplasmic reticulum. (Supplementary material for this article can be found on the International Journal of Cancer website at http://www.interscience. wiley.com/jpages/0020‐7136/suppmat/index.html). © 2005 Wiley‐Liss, Inc.
ISSN:0020-7136
1097-0215
DOI:10.1002/ijc.21235